Helixmith Co., Ltd.

11:15 AM - 11:30 AM (EST), Monday, February 6, 2023 ・ Music Box
Helixmith is a late-stage clinical development company conducting several phase 2 and phase 3 clinical trials, primarily in the US. The company is listed on Korea’s stock market, the KOSDAQ (084990).

Helixmith has several disease programs at various clinical stages, from phase 1 to phase 3: gene therapy for diabetic complications (DPN, DFU), gene therapy for lower limb disorder (claudication, DFU, CLI), and an ALS-focused program.

All are based on a scientific platform capitalizing on HGF/c-Met signaling, and three modalities have been developed to maximize this clinically important signaling pathway.

Helixmith has an ALS-focused program called DART (Defeating ALS through Regenerative Therapeutics), in which a multi-modal parallel approach is taken, involving three different drug candidates.

Helixmith is also will discuss their other programs in diabetic complications, lower limb disorder, or neuromuscular diseases.
Company Type:
Publicly Traded Company
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Senior Director, Medical Affairs Strategy
Helixmith Co., Ltd